OTCMKTS:BPMUF Basilea Pharmaceutica Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.52 0.00 (0.00 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$55.52Now: $55.52▼$55.5250-Day Range$55.47MA: $55.56▼$55.7752-Week Range$36.95Now: $55.52▼$60.05VolumeN/AAverage Volume100 shsMarket Capitalization$596.28 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestSocial Media Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, excluding ventilator-associated pneumonia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor targeting cell signaling pathways. The company was founded in 2000 and is headquartered in Basel, Switzerland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Basilea Pharmaceutica. Previous Next 2.2 Community Rank Outperform VotesBasilea Pharmaceutica has received 38 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBasilea Pharmaceutica has received 48 “underperform” votes. (Add your “underperform” vote.)Community SentimentBasilea Pharmaceutica has received 55.81% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Basilea Pharmaceutica and other stocks. Vote “Outperform” if you believe BPMUF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPMUF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBasilea Pharmaceutica does not currently pay a dividend.Dividend GrowthBasilea Pharmaceutica does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Basilea Pharmaceutica insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Basilea Pharmaceutica are expected to grow in the coming year, from ($2.19) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Basilea Pharmaceutica is -26.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Basilea Pharmaceutica is -26.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.57 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BPMUF Previous Symbol CUSIPN/A CIKN/A Webwww.basilea.com Phone41-61-606-1111Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$135.28 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value($7.88) per share Price / Book-7.05Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees227 Outstanding Shares10,740,000Market Cap$596.28 million Next Earnings DateN/A OptionableNot Optionable $55.52 0.00 (0.00 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BPMUF News and Ratings via Email Sign-up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Basilea Pharmaceutica (OTCMKTS:BPMUF) Frequently Asked Questions How has Basilea Pharmaceutica's stock price been impacted by COVID-19? Basilea Pharmaceutica's stock was trading at $44.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BPMUF shares have increased by 25.3% and is now trading at $55.52. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Basilea Pharmaceutica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Basilea Pharmaceutica. Who are some of Basilea Pharmaceutica's key competitors? Some companies that are related to Basilea Pharmaceutica include I-Mab (IMAB), Aimmune Therapeutics (AIMT), Xencor (XNCR), Opko Health (OPK), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Corcept Therapeutics (CORT), Myovant Sciences (MYOV), Harmony Biosciences (HRMY), Seres Therapeutics (MCRB), Zymeworks (ZYME), CytoDyn (CYDY), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI) and Aurinia Pharmaceuticals (AUPH). View all competitors. Who are Basilea Pharmaceutica's key executives? Basilea Pharmaceutica's management team includes the following people: Mr. David Veitch, Chief Exec. Officer (Age 54)Mr. Adesh Kaul, Chief Financial Officer (Age 45)Dr. Laurenz Kellenberger, Chief Scientific Officer (Age 52)Dr. Marc Engelhardt, Chief Medical Officer (Age 55)Dr. Gerrit Hauck, Chief Technology Officer (Age 55) What is Basilea Pharmaceutica's stock symbol? Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF." How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Basilea Pharmaceutica's stock price today? One share of BPMUF stock can currently be purchased for approximately $55.52. How big of a company is Basilea Pharmaceutica? Basilea Pharmaceutica has a market capitalization of $596.28 million and generates $135.28 million in revenue each year. The company earns $-22,490,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Basilea Pharmaceutica employs 227 workers across the globe. What is Basilea Pharmaceutica's official website? The official website for Basilea Pharmaceutica is www.basilea.com. How can I contact Basilea Pharmaceutica? Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at 41-61-606-1111 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
